Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Minimal Residual Disease Market to Exhibit Growth at a Massive CAGR of 18% During the Study Period (2019-2032), Assesses DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

01 Mar, 2023, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the minimal residual disease market are anticipated to change as the future of guided therapies, improvements in the next-generation sequencing detection methods, and the increased use of MRD testing can increase the market share in the near future

LAS VEGAS, March 1, 2023 /PRNewswire/ -- DelveInsight's Minimal Residual Disease Market Insights report includes a comprehensive understanding of current treatment practices, minimal residual disease emerging products, market share of individual products, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Minimal Residual Disease Market Report

  • As per DelveInsight analysis, the minimal residual disease market size in the 7MM was approximately 700 million in 2021.
  • According to the assessment done by DelveInsight, the total minimal residual disease testing cases in the 7MM were found to be USD 1.2 million in 2021. 
  • Leading minimal residual disease companies, such as Adaptive Biotechnologies, Foresight Diagnostics, Ceregentis B.V., ICON Plc, 3B BlackBio-Biotech, Natera, EntroGen, Quest Diagnostics, Hangzhou ImmuQuad Biotechnologies, Mission Bio, Biocartis, and others are involved in the development of diagnostic methods for the diagnosis of MRD in patients with cancer. The introduction of these methods might get an advantage in market space due to course.
  • The promising minimal residual disease products include ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Signatera, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, LymphoTrack, Idylla Technology, and others.

Discover which product will grab the major minimal residual disease market share @ Minimal Residual Disease Market Report

Minimal Residual Disease Overview

Minimal residual disease (MRD) is a small number of cancer cells that remain in the body after treatment. These cells have the potential to resurface and cause a relapse. In leukemia, for example, physicians look for a response after chemotherapy treatment by looking for cancer cells in a bone marrow biopsy under a microscope. An MRD positive test result indicates that the disease remained after treatment. An MRD negative result indicates that no disease was detected after treatment. Patients with MRD may have so few remaining cancer cells that traditional tests, such as viewing cells under a microscope, cannot detect them.

Measurable or minimal residual disease (MRD) testing is used to determine whether or not cancer treatment is effective and to guide future treatment plans. MRD testing is currently being studied in other cancers besides blood cancers (leukemia, lymphoma, and myeloma). Because the results can be used to tailor your treatment plan, it is a type of personalized medicine. MRD tests employ extremely sensitive techniques such as multiparametric flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS).

Minimal Residual Disease Epidemiology Segmentation

DelveInsight estimates that in the year 2021, the total minimal residual disease testing cases in the 7MM were found to be 1.2 million. The most number of MRD testing cases were found in the US, followed by Germany.

In Germany, the total number of MRD testing during new therapy and maintenance was found to be approximately 38 thousand and 97 thousand, respectively, in the year 2021.

The minimal residual disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total MRD testing
  • Total MRD cases by cancer type 
  • Total MRD testing from different blood cancers 
  • Total MRD testing for HSCT-related transplant 
  • Total MRD testing during new therapy and maintenance therapy
  • Total number of MRD Testing by age 

Download the report to understand which factors are driving minimal residual disease epidemiology trends @ Minimal Residual Disease Epidemiological Insights

Minimal Residual Disease Testing Market Insights

MRD is detected using highly sensitive methods such as multiparameter flow cytometry (MFC), which detects antigen expression on neoplastic cells compared to normal cells, polymerase chain reaction (PCR), which increases trace amounts of DNA so that a specific segment of DNA can be studied, and next-generation sequencing (NGS). Currently, patients are treated until they achieve complete remission (CR). This could be accomplished through surgical resection, radiation therapy, chemotherapy, or a combination of these treatments. Patients are usually monitored until they relapse. Instead, MRD could be sampled iteratively, tested for therapeutic susceptibility, and treated with the agents identified as most effective by that test. When a patient's MRD falls below the minimum detectable threshold (dashed line), treatment can be stopped, continued indefinitely, or continued with curative intent for a set period.

The ClonoSEQ is the first FDA-approved assay for detecting measurable residual disease. It detects MRD in bone marrow from patients with multiple myeloma (MM) and B-cell lymphoblastic leukemia (ALL), as well as blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). The clonoSEQ is an MRD assessment tool that uses next-generation sequencing (NGS) technology and is distinguished from other NGS assays by groundbreaking chemistry advances and proprietary bioinformatics.

To know more about minimal residual disease testing guidelines, visit @ Minimal Residual Disease Testing Methods 

Minimal Residual Disease Products and Key Companies

  • ClonoSEQ: Adaptive Biotechnologies
  • PhasED-Seq: Foresight Diagnostics
  • Targeted Locus Amplification (TLA) technology: Cergentis B.V.
  • MRDx BCR-ABL Test: ICON plc
  • TRUPCR® PML-RARA: 3B BlacBio Biotech India
  • Signatera: Natera
  • Leukemia Fusion Gene One-Step Detection Kits: EntroGen
  • CBFB/MYH11 inv(16): Quest Diagnostics
  • Seq-MRD: ImmuQuad
  • LymphoTrack: Invivoscribe Inc.
  • Idylla Technology: Biocartis

Learn more about the FDA-approved products for minimal residual disease @ New Methods for Minimal Residual Disease Testing

Minimal Residual Disease Market Dynamics

The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.

In addition, increased use of MRD testing can open up new avenues by identifying patients who may benefit from consolidative HDT-ASCT and prolonged therapy. Furthermore, the development of more precise diagnostic methods with high sensitivity allows for the detection of even the smallest number of MRD cells.

However, MRD causes cancer relapse because antibodies may disappear with appropriate treatment but reappear with tumor relapse. A lack of proper diagnostic and treatment guidelines can hamper patients' conditions. Furthermore, the diagnostic scenario in the United States differs from that in Europe and Japan. There are only a few approved testing methods for assessing MRD in the United States. The MRD market is characterized by a lack of disease understanding, limited epidemiological studies, and assessment options. There is a need to develop effective patient-specific assessment options, including age. However, there is a significant unmet need to establish MRD biology for a better understanding of the disease and a significant need for expertise to carry out MRD assays.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Base Year

2019

Minimal Residual Disease Market CAGR

14 %

Minimal Residual Disease Market Size in 2021

USD 1.2 Million

Key Minimal Residual Disease Companies

Adaptive Biotechnologies, Foresight diagnostics, Ceregentis B.V., ICON Plc, 3B BlackBio-Biotech, Natera, Entrogen, Quest diagnostics, Hangzhou ImmuQuad Biotechnologies, Mission Bio, Biocartis, and others

Key Minimal Residual Disease Products

ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Signatera, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, LymphoTrack, Idylla Technology, and others

Scope of the Minimal Residual Disease Market Report

  • Therapeutic Assessment: Minimal Residual Disease current marketed and emerging therapies
  • Minimal Residual Disease Market Dynamics: Minimal Residual Disease market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Minimal Residual Disease Market Access and Reimbursement

Discover more about minimal residual disease testing products in development @ Minimal Residual Disease Testing Clinical Trials

Table of Contents

1.

Minimal Residual Disease Market Key Insights

2.

Minimal Residual Disease Market Report Introduction

3.

Minimal Residual Disease Market Overview at a Glance

4.

Minimal Residual Disease Market Executive Summary

5.

Disease Background and Overview

6.

Minimal Residual Disease Treatment and Management

7.

Minimal Residual Disease Epidemiology and Patient Population

8.

Patient Journey

9.

Minimal Residual Disease Marketed Drugs

10.

Minimal Residual Disease Emerging Drugs

11.

Seven Major Minimal Residual Disease Market Analysis

12.

Minimal Residual Disease Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Minimal Residual Disease Market Drivers

16.

Minimal Residual Disease Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Hematological Cancer Therapeutics Market

Hematological Cancer Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hematological cancer therapeutics companies, including Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Relapsing Refractory Multiple Myeloma Market

Relapsing Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Lymphocytic Leukemia Pipeline

Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs 

Multiple Myeloma Treatment Market 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services 

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.